CD274 and neoplasm: In particular, we highlight the expression mechanism of immune checkpoint PD-(L)1 in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting vital metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials.